MedTrace Logo

Metformin in Postmenopausal Women With Metabolic Syndrome

NCT01342744 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-05-17

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of metformin on cardiovascular risk factors in postmenopausal women with metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Metformin

Metformin(850 mg) 1tab oral twice aday

DRUG

Placebo

Placebo 1 tab oral twice a day

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Suchada Indhavivadhana, M.D. · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Thailand

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342744 on ClinicalTrials.gov